Lexicon Pharmaceuticals (LXRX) Short-term Investments (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Short-term Investments data on file, last reported at $132.6 million in Q1 2026.

• On a quarterly basis, Short-term Investments changed 0.47% year-over-year to $132.6 million in Q1 2026; TTM through Mar 2026 was $132.6 million, a 0.47% change from a year earlier, with the FY2025 full-year figure at $61.9 million, down 63.86% from the prior year.
• Short-term Investments for Q1 2026 stood at $132.6 million, up from $61.9 million in the prior quarter.
• Over the last five years, Short-term Investments for LXRX reached as high as $274.3 million in Q2 2024 and fell as low as $27.0 million in Q1 2022.
• Historically, Short-term Investments has averaged $135.0 million across 5 years, with a median of $132.0 million in 2025.
• Across the five-year window, Short-term Investments surged 307.53% in 2022 and tumbled 70.38% in 2025, its largest moves.
• Year by year, Short-term Investments stood at $92.0 million in 2022, then soared by 60.37% to $147.6 million in 2023, then increased by 16.09% to $171.3 million in 2024, then plunged by 63.86% to $61.9 million in 2025, then jumped by 114.15% to $132.6 million in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $132.6 million in Q1 2026, $61.9 million in Q4 2025, and $66.3 million in Q3 2025.